Legal, PR Efforts Ramp Up To Target J&J On Vaginal Mesh Device Issues
This article was originally published in The Gray Sheet
The Corporate Action Network has launched a new website intended to shame the firm for practices tied to its withdrawn pelvic mesh implant devices, while requesting a Department of Justice investigation into the firm’s document-destruction activities and hatching plans to disrupt J&J’s annual shareholder meeting.
You may also be interested in...
Janssen subsidiary pleads guilty as part of $2.2 billion deal that also requires audits of sales rep compensation.
Firm is stopping sales of four of its vaginal mesh products in the face of over 1,000 product liability lawsuits and FDA requirements for post-market safety and efficacy studies.
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.